4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
Total Valuation
4D Molecular Therapeutics has a market cap or net worth of $483.97M. The enterprise value is $445.14M.
Market Cap$483.97M
Enterprise Value$445.14M
Share Statistics
4D Molecular Therapeutics has 51,051,487 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,051,487
Owned by Insiders0.38%
Owned by Institutions43.86%
Financial Efficiency
4D Molecular Therapeutics’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -30.20%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)-30.20%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee375.37K
Profits Per Employee-617.22K
Employee Count227
Asset Turnover0.15
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of 4D Molecular Therapeutics is ―. 4D Molecular Therapeutics’s PEG ratio is 0.17.
PE Ratio―
PS Ratio5.10
PB Ratio0.86
Price to Fair Value0.86
Price to FCF-3.98
Price to Operating Cash Flow-5.03
PEG Ratio0.17
Income Statement
In the last 12 months, 4D Molecular Therapeutics had revenue of 85.21M and earned -140.11M in profits. Earnings per share was -2.42.
Revenue85.21M
Gross Profit77.58M
Operating Income-159.55M
Pretax Income-140.11M
Net Income-140.11M
EBITDA-151.92M
Earnings Per Share (EPS)-2.42
Cash Flow
In the last 12 months, operating cash flow was -109.08M and capital expenditures -1.24M, giving a free cash flow of -110.32M billion.
Operating Cash Flow-109.08M
Free Cash Flow-110.32M
Free Cash Flow per Share-2.16
Dividends & Yields
4D Molecular Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.76
52-Week Price Change257.74%
50-Day Moving Average9.03
200-Day Moving Average8.09
Relative Strength Index (RSI)53.38
Average Volume (3m)736.92K
Important Dates
4D Molecular Therapeutics upcoming earnings date is May 7, 2026, After Close (Confirmed).
Last Earnings DateMar 18, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
4D Molecular Therapeutics as a current ratio of 9.39, with Debt / Equity ratio of 4.23%
Current Ratio9.39
Quick Ratio9.39
Debt to Market Cap0.05
Net Debt to EBITDA0.26
Interest Coverage Ratio0.00
Taxes
In the past 12 months, 4D Molecular Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
4D Molecular Therapeutics EV to EBITDA ratio is -2.60, with an EV/FCF ratio of -3.63.
EV to Sales4.64
EV to EBITDA-2.60
EV to Free Cash Flow-3.63
EV to Operating Cash Flow-3.63
Balance Sheet
4D Molecular Therapeutics has $402.65M in cash and marketable securities with $21.41M in debt, giving a net cash position of $381.24M billion.
Cash & Marketable Securities$402.65M
Total Debt$21.41M
Net Cash$381.24M
Net Cash Per Share$7.47
Tangible Book Value Per Share$8.73
Margins
Gross margin is -14.04%, with operating margin of -187.24%, and net profit margin of -164.43%.
Gross Margin-14.04%
Operating Margin-187.24%
Pretax Margin-164.43%
Net Profit Margin-164.43%
EBITDA Margin-178.29%
EBIT Margin-187.24%
Analyst Forecast
The average price target for 4D Molecular Therapeutics is $31.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$31.43
Price Target Upside231.54% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast―